Milestone Pharmaceuticals, Inc.
https://www.milestonepharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Milestone Pharmaceuticals, Inc.
Milestone Taking Etripamil Into Phase III For AFib Based On Phase II Success
The company’s calcium channel blocker nasal spray rapidly slowed atrial fibrillation patients’ heart rates, showing potential to be an at-home replacement for emergency room-administered treatment.
Acesion Seeks Partner For First-In-Class AF Program Following Phase II Success
Having reached proof-of-concept for its first-in-class SK ion channel inhibitor for atrial fibrillation, the Danish firm is on the hunt for a licensee as it moves its attention to its preclinical program for sinus rhythm maintenance.
Milestone Hits Mark With RAPID Path To Potential Blockbuster Sales
The company plans to file for approval of etripamil in paroxysmal supraventricular tachycardia (PSVT) in mid-2023, with the drug having the possibility to reach sales of $1bn or more.
Asia Deal Watch: Heartseed Licenses Lead Cell Therapy Candidate To Novo Nordisk
Novo gets worldwide development and commercial rights except for Heartseed’s home market in Japan. LianBio unveils licensing partnerships with Lyra, Landos and Nanobiotix.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice